STEMLINE THERAPEUTICS INC
STEMLINE THERAPEUTICS INC (STML): 11 pipeline candidates · ~33 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
32.8 months
D/E 0.16 · 0% dilution
Lead: Approved
11 candidates
N/A
N/A
A transparent, data-derived signal for STEMLINE THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$29.2M
Quarterly Burn
$13.8M
Runway
32.8 mo
Revenue
$8.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| elacestrant | Phase 1 |
| elzonris | Approved |
| felezonexor | Phase 1 |
| men2312 | Phase 1 |
| men2501 | Phase 1 |
| sl-1001 | Preclinical |
| sl-401 | BLA Filed |
| sl-701 | Phase 2 |
| sl-801 | Phase 1 |
| sl-901 | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in STEMLINE THERAPEUTICS INC's pipeline?
STEMLINE THERAPEUTICS INC (STML) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is STEMLINE THERAPEUTICS INC's lead drug candidate?
STEMLINE THERAPEUTICS INC's most advanced tracked candidate is elacestrant (Phase 1) for Breast Neoplasms; Advanced Breast Cancer; Metastatic Breast Cancer.
What is STEMLINE THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, STEMLINE THERAPEUTICS INC has approximately 32.8 months of cash runway.
Who is the CEO of STEMLINE THERAPEUTICS INC?
Ivan Bergstein is the chief executive officer of STEMLINE THERAPEUTICS INC (STML).
Get the full picture on STEMLINE THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.